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Abstract
Background: The prognostic impact of mild/moderate liver 
impairment among critically ill patients is not known. We 
aimed to determine whether acute liver impairment, as 
measured by several biomarkers, (i) is frequent, (ii) influ-
ences prognosis and (iii) to determine whether such an 
effect is specific for infected critically ill patients.
Methods: A biomarker and clinical cohort study based 
on a randomized controlled trial. All-cause mortality was 
the primary endpoint. Biomarkers hyaluronic acid (HA), 
bilirubin, albumin, alkaline phosphatase and the inter-
national normalized ratio (INR) were determined. Multi-
variable statistics were applied to estimate risk increase 
according to liver biomarker increase at baseline and the 
model was adjusted for age, APACHE II, severe sepsis/
septic shock vs. milder infection, chronic alcohol abuse 
Charlson’s co-morbidity index, cancer disease, surgi-
cal or medical patient, body mass index, sex, estimated 
glomerular filtration rate, mechanical ventilation and 
the other biomarkers. Time-to-event graphs were used. 
The patients were critically ill patients (n = 1096) from 
nine mixed medical/surgical intensive care units without 
known hepatobiliary disease.
Results: HA levels differed between infected patients 
(median 210.8 ng/mL [IQR: 93.2–556.6]) vs. the non-
infected (median 56.8 ng/mL [IQR: 31.9–116.8], p < 0.001). 
Serum HA quartiles 2, 3 and 4 were independent predic-
tors of 90-day all-cause mortality for the entire popula-
tion (infected and non-infected). However, the signal 
was driven by the infected patients (positive interac-
tion test, no signal in non-infected patients). Among 
infected patients, HA quartiles corresponded directly to 
the 90-day risk of dying: 1st quartile: 57/192 = 29.7%, 2nd 
quartile: 84/194 = 43.3%, 3rd quartile: 90/193 = 46.6%, 
4th quartile: 101/192 = 52.3 %, p for trend: <0.0001. This 
finding was confirmed in adjusted analyses: hazard ratio 
vs. 1st quartile: 2nd quartile: 1.3 [0.9–1.8], p = 0.14, 3rd 
quartile: 1.5 [1.1–2.2], p = 0.02, 4th quartile: 1.9 [1.3–2.6], 
p < 0.0001). High bilirubin was also an independent pre-
dictor of mortality.
Conclusions: Among infected critically ill patients, sub-
tle liver impairment, (elevated HA and bilirubin), was 
associated with a progressive and highly increased risk 
of death for the patient; this was robust to adjustment 
for other predictors of mortality. HA can identify patients 
at high risk.
Keywords: biomarkers; infection; liver impairment; 
mortality.
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Introduction
Mortality in severely infected critically ill patients remains 
high, despite recent improvements due to increased aware-
ness and prompt and effective treatment [1, 2]. Only a small 
minority of critically ill septic patients have been described 
as having acute liver failure as defined, although a clinically 
relevant definition is disputed [3, 4]. It is well-described 
that the liver has an important role in sepsis immunol-
ogy, especially in functions like endotoxin clearance via 
Kuppfer cells, synthesizing immunoactive proteins such 
as IL-6, C-reactive protein, α-1-antitrypsin, fibrinogen, and 
possibly via altering glucose homeostasis [5, 6]. Seemingly 
subtle impairments in liver function (below the threshold 
for defined acute liver failure) could, via the correspond-
ing immunological defect, be of clinical importance for the 
host response towards bacterial infection – and could have 
an impact on patient survival [7]. Classic biomarkers of liver 
injury like bilirubin, the international normalized ratio 
(INR) and aspartate aminotransferase (AST)/alanine ami-
notransferase (ALT) have several limitations in critically ill 
patients, including a lack of specificity for liver damage, as 
among others, bile duct obstruction, hemolysis, vitamin K 
antagonists, coagulopathy, hypoperfusion/hypoxemia and 
frequent genetic disorders may cause derangements without 
liver impairment [8–10]. Hyaluronic acid (HA) is a macro-
molecular component of the extracellular matrix – a frame-
work for cells throughout the body [11]. Several synthases 
produce HA (HAS-1, HAS-2, HAS-3) [12, 13] and six genes are 
responsible for six hyaluronidases (HYAL1, HYAL2, HYAL3, 
HYAL4, PH20/SPAM1 and HYALP1) [14] that degrade HA. 
The elimination of HA is primarily taken care of in the liver 
through receptor mediated endocytosis by the sinusoi-
dal endothelial cells [15], and the speed of this has been 
shown to be highly influenced by hepatic blood flow and 
hepatocyte function in animal experimental sepsis [16]. In 
a study of porcine resuscitated septic shock, high levels 
of HA were seen, indicating hepatocyte dysfunction [17]. 
This is supported by data, observing a reduced sinusoidal 
HA uptake in sepsis [18], and very high levels of HA have 
been observed in a small study of human septic shock [19]. 
Recently, the turbidimetric HA assay used in the current 
study was validated towards the traditional EIA assay in 
a clinical material and in standardized test solutions [20]. 
The turbidimetric assay allows for routine and fairly cheap 
HA analysis in most hospital laboratories.
The primary objective of the current study was to 
determine whether subtle liver impairment, measured 
by abnormal HA and other liver biomarkers, is associ-
ated with mortality in a diverse population of critically 
ill patients without known pre-existing liver disease, and 
further to determine whether a possible impact on  survival 
is  specific for severely infected patients (PCT > 1.0 ng/mL 
vs. ≤1.0 ng/mL) and to establish which liver biomarker 
could best describe the consequences of such a liver 
impairment on overall prognosis.
Secondary objectives: to determine whether there 
are strong correlations between the liver biomarkers and 
markers of endothelial dysfunction, soluble thrombomod-
ulin and syndecan-1.
Materials and methods
Study population
This was a biobank study, based on the cohort of critically ill patients 
recruited into a 1200 patient multi-center randomized good clinical 
practice-controlled trial, the Procalcitonin And Survival Study (PASS) 
from 2006 to 2011. Patients were at least 18 years old and admitted to 
one of the participating intensive care units (ICUs). The intervention 
did not influence the general prognosis. For further details, please 
see the primary PASS publication [21].
The population for the current study consisted of patients from 
sites that routinely measured bilirubin and INR with enough serum 
to perform hyaluronic acid (HA) analysis, had measurement of biliru-
bin, INR and creatinine at enrolment in the PASS trial, and who did 
not have a verified hepato-biliary disease at recruitment (Figure 1).
Biomarker measurement
HA was measured with a particle enhanced turbidimetric immunoas-
say (PETIA) (Corgenix, Broomfield, CO, USA) in samples on a Hitachi 
917 (Roche Diagnostics, GmbH, Mannheim, Germany) and in the 
dilution series on a Modular P (Roche Diagnostics GmbH, Mannheim, 
Germany) analyzers (test assay). We have earlier published an exter-
nal validation of the assay towards the previous EIA-based standard 
[20]. All assays were calibrated against a standardize calibration set 
(Corgenix, reference 13375) and quality control with a standardized 
set for this purpose (Corgenix, reference 13376). Both calibration and 
quality control were done in accordance with the manufacturer’s 
instructions. Reference levels of hyaluronic acid were defined as 
healthy blood donor HA levels [22].
Outcome assessment
The primary endpoint was “all-cause mortality within 90 days”. This 
was assessed by accessing the Danish National Patient Register. 
 Follow-up was complete (100.0%).
Statistical analyses
Comparisons of continuous data were made using Mann-Whitney 
U tests and Student’s t tests where appropriate. The chi-square test 
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for equal proportions was used to test categorical variables, at small 
numbers, using Fisher’s exact test. Time-to-event analyses were 
performed using Kaplan-Meier plots with corresponding log rank 
tests and Cox proportional hazards models. Multivariable analysis 
of the primary endpoint was performed adjusting for known and 
suspected predictors of mortality (all assessed at baseline): age (per 
year increase), APACHE II score (≥25 vs. <25), severe sepsis/septic 
shock (present vs. not), chronic alcohol abuse, Charlson’s score (≥2 
vs. <2), cancer diagnosis (yes vs. no), admitted from surgical depart-
ment (yes vs. no), body mass index (≥25 vs. <25), gender (male vs. 
female), estimated glomerular filtration rate (>60 mL/min/1.73 m2) 
vs. 30–60 mL/min/1.73 m2 vs. <30 mL/min/1.73 m2), mechanical ven-
tilation (yes vs. no).
Pearson’s correlations between liver biomarkers, endothelial 
biomarkers and infection biomarkers were calculated.
Statistical analyses were performed using SAS version 9.3 (SAS 
Institute Inc, Cary, NC, USA), version 3.0.2 (The R-project, http://
www.r-project.org/). IBM SPSS statistics 22 and Excel were used for 
graphs.
The study was initiated and run by doctors at our research 
department (CHIP, Rigshospitalet) and the participating ICUs. The 
data belong to the PASS study group.
Ethical approval
The study was approved by the appropriate Ethics Committee and 
was therefore been performed in accordance with the ethical stand-
ards laid down in the 1964 Declaration of Helsinki and its later 
amendments. The trial was approved by the regional Ethics Commit-
tee (KF 01 272 753, KF 11 297 287).
Results
Patients and follow-up
From the original randomized trial of 1200 critically ill 
patients, recruited at nine ICUs in Denmark, 1096 fulfilled 
the inclusion criteria for the current study of liver impair-
ment among critically ill patients (Figure 1).
The baseline characteristics of the patients are 
available in Table 1; almost half of the patients who 
had PCT > 1.0  ng/mL had clinically judged septic shock; 
this condition was apparent in only 10.5% of those with 
PCT ≤ 1.0 ng/mL, Table 1.
Follow-up within 28  days after inclusion was com-
plete (100%) for the primary endpoint of death from any 
cause within 90 days.
Liver biomarker levels and mortality
HA levels were abnormally high (median 141.9 ng/mL 
[IQR: 60.1–416.2]) compared to healthy blood donors 
(median 29.1 ng/mL [IQR: 19.7–40.7]). HA levels at base-
line were higher among those who were infected (median 
210.8  ng/mL [IQR: 93.2–556.6]) vs. the non-infected 
(median 56.8 ng/mL [IQR: 31.9–116.8], p < 0.001).
60 patients had too sparse
serum material at baseline to
do liver biomarker analysis
1140 intensive care patients had liver
biomarker measurements at baseline
44 patients had a chronic liver
disease
1096 intensive care patients with no
chronic liver disease and sufficient
serum for biomarker analysis
1096 intensive care patients entered
the study for biomarker analysis and
statistical analysis. Data are reported
for all the patients who entered
1200 medical and surgical intensive care
patients randomized into the PASS trial
‘The PASS Cohort’
Figure 1: Flow of patients in the study.
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HA levels differed most; to a lesser extent INR, bili-
rubin and albumin. Alkaline phosphatase did not differ 
between infected and non-infected patients, except on 
day 2, Supplementary digital Table 1.
As expected, most of the tested liver biomarkers 
were correlated to each other (Pearson’s correlation 
coefficients ranging between 0.15 and 0.33 [numeric]), 
Figure 2. Interestingly, HA, bilirubin and the model for 
end-stage liver disease (MELD) score were all moderate-
highly correlated to the endothelial markers (sTM and 
syndecan-1), Figure 2.
HA levels tended to be higher on day 3 among those 
patients initially randomized to high exposure to broad-
spectrum antibiotics, however, this was not a significant 
difference, p = 0.10, Wilcoxon signed rank test.
In infected ICU patients, HA serum level quar-
tiles corresponded directly and stepwise to the 90-day 
risk of dying: 1st quartile: 57/192 = 29.7%, 2nd quartile: 
84/194 = 43.3%, 3rd quartile: 90/193 = 46.6%, 4th quar-
tile: 101/192 = 52.3 %, p for trend: <0.0001. The cumulative 
hazard for all-cause mortality, corresponding to liver bio-
marker levels, is shown in Figure 3; for HA, bilirubin and 
MELD, there was a highly significant increase in mortality 
risk according to biomarker levels. HA seemed to have the 
clearest and most direct correspondence between serum 
levels and mortality risk, reaching excessive high risk in 
3rd and 4th quartiles.
To control for known and possible confounders, we 
built a Cox proportional hazards model for each biomarker, 
including predictors of mortality defined in the literature 
Table 1: Baseline characteristics of the patients, n = 1096.
Patient groups   Infected (PCT > 1.0 ng/mL)
(n = 772)
  Non-infected (PCT ≤ 1.0 ng/mL)
(n = 324)
General features    
 Age (years), median (IQR)   68 (60–74)   68 (58–77)
 Gender (female)   346 (44.8)   158 (48.8)
 Body mass index (kg/m2), median (IQR)   25 (22–28)   25 (23–28)
Acute illness    
 APACHE II Score, median (IQR)   20 (14–26)   15 (10–20)
 Temperature (oC), median (IQR)   37.4 (36.5–38.2)   37.0 (36.2–37.7)
 Glasgow Coma scale, median (IQR)   15 (15–15)   15 (15–15)
 Mechanical ventilation   525 (68.0)   204 (63.0)
 Surgical department before intensive care  231 (30.0)   75 (23.2)
 Septic shock, n (%)   368 (47.7)   34 (10.5)
Chronic health    
 Chronic alcohol abuse, n (%)   52 (6.7)   23 (7.1)
 Cancer, n (%)   102 (13.2)   29 (9.0)
 Chronic obstructive lung disease, n (%)   124 (16.1)   108 (33.3)
 Charlson’s score category, n (%)    
  0   304 (39.4)   73 (22.5)
  1   222 (28.8)   135 (41.7)
  2   163 (21.1)   82 (25.3)
  3   54 (7.0)   26 (8.0)
  4   19 (2.5)   6 (1.9)
  5   2 (0.3)   1 (0.3)
  6   7 (0.9)   1 (0.3)
  7   1 (0.1)   0 (0.0)
Markers of hepatic and renal function    
 HA, ng/mL, median (IQR)   211 (93–557)   57 (32–117)
 INR, median (IQR)   1.4 (1.2–1.6)   1.1 (1.0–1.3)
 Albumin (μmol/L), median (IQR)   313 (227–405)   421 (316–508)
 Bilirubin (μmol/L), median (IQR)   10 (6–18)   7 (4–12)
 Alkaline phosphatase (U/L), median (IQR)   84 (55–123)   83 (61–116)
 MELD, median (IQR)   16 (11–21)   9 (7–13)
 Creatinine (μmol/L), median (IQR)   143 (91–231)   85 (62–116)
IQR, interquartile range; HA, hyaluronic acid; INR, international normalized ratio; MELD, model for end-stage liver disease. Baseline was 
defined as the first calendar date the patient was included into the study and this was maximum 24 h later than intensive care admission.
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[23, 24] and based on our own previous data [25]. Elevated 
HA and bilirubin were associated with an increased risk of 
death in multivariable analysis; in unadjusted analysis, all 
the liver biomarkers predicted mortality, Table 2.
To find out if liver impairment carries a high mortal-
ity risk in critically ill patients as such, and if this risk 
is linked to the liver’s function in the immune defense 
towards infection, we did an interaction analysis, testing 
the interaction between PCT below or above 1.0 ng/mL vs. 
HA levels in quartiles towards all-cause 90-day mortality. 
We found an interaction, p = 0.04. Finally, applying the 
Cox regression model to all the non-infected critically ill 
patients, no increased risk was detected in patients with 
abnormal liver function tests, p-value range: 0.18–0.93.
Testing liver biomarker quartiles for HA, bilirubin, INR 
and MELD, while adjusting for each other in the infected 
population, we found a highly significant increased risk 
of death for every quartile increase in hazard ratio (HA 
[every quartile increase]: 1.2 [95% CI: 1.1–1.3], p = 0.005), 
whereas this was not the case for the other liver biomark-
ers (p-values ranging 0.12–0.88).
The ability of APACHE II to predict 90-day mortality 
was increased from an AUC of 0.625–0.650 when the HA 
was added. We estimated the net reclassification improve-
ment (NRI) and the integrated discrimination improve-
ment (IDI) by using two logistic regression models for 
APACHE II (classic) and for APACHE II (enriched with HA) 
towards the 90-day mortality. The NRI was 0.27 ([95% CI: 
0.15–0.38], p = 5.1 × 10−6) and the IDI was 0.0225 (95% CI: 
0.013–0.032), p = 2.4 × 10−6).
In the model of the infected patients, to explore 
whether high exposure of broad-spectrum antibiotics, 
as administered in the intervention arm of the PASS trial, 
interacted with the prediction estimate of the hyaluronic 
acid, we tested whether the randomization group inter-
acted with the hyaluronic acid quartiles in the prediction 
estimate of the Cox model; this was not the case, p-value 
for interaction 0.24.
Correlation to hyaluronic acid
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Albumin
–0.80 –0.60 –0.40 –0.20 0.00
r, 95% CI
0.20 0.40 0.60 0.80
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Figure 2: Correlations between the liver markers and the endothelial damage markers.
MELD, model for end-stage liver disease; sTM, soluble thrombomodulin; INR, international normalized ratio. 
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Discussion
In a broad population of infected critically ill patients, 
subtle changes in liver function added a striking high and 
independent risk of dying within 3 months. This was con-
firmed by analyzing several different liver biomarkers. HA 
seemed to capture this subtle liver function impairment 
most comprehensively.
It is unknown whether such a subtle liver impair-
ment in general carries a mortality risk increase in criti-
cally ill patients, or whether this effect is linked to the 
liver’s role in host defense towards infections. To further 
substantiate this, we compared the impact of liver 
impairment in patients who did not suffer from severe 
infection (PCT < 1.0  ng/mL) with the impact of liver 
impairment among patients with more severe infection 
(PCT ≥ 1.0 ng/mL). The results were clear; when exploring 
mortality, we found a strong interaction between severe 
infection and liver impairment (p = 0.04). When subse-
quently analyzing the subgroup of patients, who did not 
have severe infection (PCT < 1.0 ng/mL), no liver variable 
carried an increased mortality risk.
Compared to other types of organ failure, like acute 
respiratory failure, acute kidney failure and acute heart 
failure, not much attention has been placed on liver dys-
function in sepsis and critical illness. Little is known 
about the mortality attributed to liver impairment in crit-
ically ill patients, and whether this is linked to infection 
and whether biomarkers can detect this liver impairment 
early after admission to the ICU [7, 26]. In sepsis patients, 
the prevalence of liver dysfunction is not certain as esti-
mates range from 1% to 26% in larger patient materi-
als [3, 7]; however, it has been concluded that the lack 
of reliable diagnostic tools, preclude the early detec-
tion of liver impairment in sepsis. We found that nearly 
85% of the ICU patients have abnormally high HA levels 
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Figure 3: Mortality and liver biomarker quartiles.
INR, international normalized ratio; MELD, model for end-stage liver disease.
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compared to levels in blood donors. Fifty percent of the 
infected critically ill patients with the highest HA (3rd 
and 4th quartiles) have significantly increased 90-day 
mortality; a finding robust for adjustment for a range of 
known and suspected predictors of mortality. Addition-
ally, when entering all the tested liver biomarkers into 
a multivariable analysis, thus adjusting for each other, 
only HA and bilirubin predicted mortality. Thus, abnor-
mal HA levels are frequent in critically ill patients. In 
the infected critically ill patients at least 50% of those 
who have HA levels at baseline above the median, have 
severely compromised prognosis compared to those with 
HA in the lowest quartile.
This strongly questions whether the currently used 
definitions of liver impairment are relevant for septic 
critically ill patients [3, 4] and should increase awareness 
towards liver-function preserving interventions which 
are urgently needed in a multifaceted sepsis manage-
ment approach. Using the SOFA score hepatic component 
(bilirubin-based), the incidence of hepatic dysfunction 
was estimated in larger studies to be 36–47%, which 
approaches our observations, however, the impact on 
mortality has not been systematically explored in these 
studies [27, 28].
In sepsis, the role of the liver is not fully understood; 
however, it is clear that the liver has important functions 
in the host response towards bacterial infection. The liver 
acts as a scavenger for bacteria and bacterial products 
[29, 30]. An active crosstalk takes place between blood 
cells and different liver cells like hepatocytes, Kupffer 
cells and sinusoidal endothelial cells to regulate the pro- 
and anti-inflammatory response in sepsis. Hepatic lipo-
protein clearance in sepsis seems to be highly dependent 
on Proprotein convertase subtilisin/kexin type 9 (PCSK9), 
as inhibition of this system leads to lower bacterial loads, 
a lower degree of liver and kidney pathology and lower 
IL-10 and myeloperoxidase levels [31]. Additionally, pro-
found changes in coagulation take place in sepsis via 
antithrombin and protein C downregulation resulting in 
an early pro-coagulant state; the magnitude of the latter 
possibly being influenced by the degree of liver impair-
ment during the septic insult [32].
Based on our results it seems plausible that severe 
dysregulation of these hepatic systems, involved in the 
response to bacterial infection, can affect the course of the 
infection and thereby the mortality risk.
Most of the liver biomarkers, and especially HA, 
were correlated to the biomarkers of endothelial function 
(sTM and syndecan-1), indicating a link to the endothe-
lial damage often present in sepsis. It was beyond the 
scope of the current study to conclude whether this link Ta
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is primarily via hepatic sinusoid endothelial cells, or to 
a higher extent, via non-hepatic endothelium. However, 
as this correlation between HA and endothelial markers 
is not very strong, it seems there must be other important 
host defense functions that are compromised in sepsis-
related hepatic impairment.
Interestingly, while HA levels were closely linked to 
prognosis among patients with severe infection, increased 
levels of HA were not associated with prognosis among 
patients without severe infection (p for interaction  =  0.04. 
This discrepancy strongly suggests that the role of the liver 
is pivotal in sepsis survival, and that a beneficial response 
to bacterial infection is dependent on the degree of sepsis-
related liver damage.
Strengths and limitations
The current study is a biobank study with a linked cohort, 
carrying the built-in limitations of cohort studies com-
pared to randomized trials. As some departments in the 
trial did not routinely measure INR, more than 200 patients 
had missing values on this parameter. In 75 patients, there 
was an insufficient volume of serum, and we cannot 
expand our conclusions to the patients where biomarkers 
were not measured. The strengths of the study are (i) the 
relatively high sample size – the sample size of 1096 is 
to the best of our knowledge the largest total number of 
critically ill patients available with a suitable biobank for 
hepatic biomarker analysis (ii) the complete follow-up for 
the endpoints due to good clinical practice-based clinical 
monitoring and follow-up based on the Danish hospital 
registers, and (iii) the completeness of data on a wide 
variety of clinical, biochemical and microbiological data 
in these patients. Additionally, we were able to identify 
patients with verified chronic liver disease, and by exclud-
ing these the influence of chronic liver failure is less likely 
to influence the results.
Conclusions
In summary, sepsis-related acute liver impairment (SALI) 
is present early in the ICU admission, is frequent, and 
is associated with a high mortality rate. In not severely 
infected patients, liver impairment did not seem to influ-
ence mortality. HA and bilirubin could identify patients 
at risk, HA seems to capture this excess risk for more 
patients. Mortality estimates were progressively higher for 
every quartile HA increased.
In the understanding and management of severe 
bacterial infections, more attention is needed on hepatic 
function and how the liver host response is preserved in 
sepsis. Future trial targets could aim at preserving Kupffer 
cells, hepatocytes and sinusoidal endothelial cell early 
in sepsis. Monitoring of septic ICU patients with HA on a 
daily basis could be implemented as a way to differenti-
ate infection treatment response, both regarding hepatic 
impairment and overall prognosis.
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